Findings

What do systematic reviews say?

69 questions · 69 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 64 · 92.8%Very low 1 · 1.4%Low 3 · 4.3%Moderate 1 · 1.4%High 0 · 0%

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Laser (low level) led to lower oral mucositis (moderate to severe) compared with povidone; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.29 [0.16, 0.54]
1 study · 50 participants
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
no estimate extracted
2 studies
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Epidermal growth factor led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.67 [0.45, 0.99]
1 study · 103 participants
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Pentoxifylline showed no clear difference in oral mucositis (moderate to severe) compared with no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1 [0.68, 1.47]
1 study · 140 participants
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Glutamine showed no clear difference in oral mucositis (moderate to severe) compared with placebo/usual care; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.88 [0.69, 1.12]
5 studies
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Indomethacin showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1 [0.82, 1.23]
1 study · 18 participants
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.71 [0.47, 1.07]
1 study · 66 participants
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Camomile showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.63 [0.33, 1.22]
1 study · 164 participants
GRADE not reported

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Keratinocyte GF 50 mg showed no clear difference in oral mucositis (moderate to severe) compared with keratinocyte GF 25 mg; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.78 [0.4, 1.49]
1 study · 28 participants
GRADE not reported